Abstracts Archive - Page 1553 of 2425 - ACR Meeting Abstracts

Abstract Number: 2036 • 2016 ACR/ARHP Annual Meeting
Whole Exome Sequencing in Early Onset Systemic Lupus Erythematosus
Ezgi Deniz Batu¹, Can Kosukcu², Ekim Z. Taskiran², Sema Akman³, Kubra Ozturk⁴, Betul Sozeri⁵, Erbil Unsal⁶, Zelal Ekinci⁴, Yelda Bilginer⁷, Mehmet Alikasifoglu² and Seza Ozen⁸, ¹Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ²Department of Medical Genetics, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ³Department of Pediatrics, Division of Nephrology-Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ⁴Department of Pediatrics, Division of Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey, ⁶Dokuz Eylul University, Izmir, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder with different genetic and environmental factors playing role in its pathogenesis. Early onset SLE, familial…
Abstract Number: 2037 • 2016 ACR/ARHP Annual Meeting
Proteostasis Dysregulation and Autoinflammation in Patients with TRNT1 Deficiency
Angeliki Giannelou¹, Qing Zhou², Hongying Wang³, Abu-Asab Mones⁴, Hong-Wei Sun⁵, Deborah L. Stone⁶, Amanda K. Ombrello⁷, Wanxia L. Tsai⁸, Stephen Brooks⁹, Jehad H. Edwan⁵, Kimberly Risma¹⁰, Lucie Sramkova¹¹, Abdullah Al Sonbul¹², Sarita Joshi¹³, Helen C. Su¹⁴, Karyl Barron¹⁴, Massimo G. Gadina¹⁵, Gustavo Gutierrez-Cruz⁵, Markus Hafner⁵, Ivona Aksentijevich¹⁶ and Daniel L. Kastner¹⁶, ¹National Human Genome Research Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Inflammatory Disease Branch, Bethesda, MD, ³National Human Genome Research Institute, Bethesda, MD, ⁴National Eye Institute, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁷Inflammatory Disease Section, NHGRI, National Institutes of Health, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁹NIAMS/NIH, Bethesda, MD, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Charles University 2nd Faculty of Medicine and UH Motol, Prague, Czech Republic, ¹²King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, ¹³Nationwide Children's Hospital, Columbus, OH, ¹⁴National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁵Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶National Human Genome Research Institute, National Institutes of Health, Inflammatory Disease Section, Bethesda, MD
Background/Purpose: Hypomorphic mutations in the TRNT1gene result in a syndrome of sideroblastic anemia, immunodeficiency, periodic fevers and developmental delay (SIFD). The TRNT1 enzyme is essential…
Abstract Number: 2038 • 2016 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer E. Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon M. Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁶Hackensack Univ Med Ctr, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 2040 • 2016 ACR/ARHP Annual Meeting
Responsiveness of Patient Reported Outcomes Measurement Information System Measures in RA Patients Starting or Switching a DMARD
Alyssa Wohlfahrt¹, Clifton Bingham III², Zhi Zhang¹, Marcy Bolster³, Larry W. Moreland⁴, Tuhina Neogi⁵, Kristine Phillips⁶ and Yvonne C. Lee⁷, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The Patient Reported Outcome Measurement Information System (PROMIS) is an NIH-developed metric for assessing multidimensional aspects of health across different conditions. Prior RA studies…
Abstract Number: 2041 • 2016 ACR/ARHP Annual Meeting
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form in Patients with SLE
Shanthini Kasturi¹, Jayme C. Burket², Jessica Berman¹, Kyriakos A. Kirou¹, Alana B. Levine¹, Lisa R. Sammaritano¹ and Lisa Mandl¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: The measurement of patient reported outcomes (PROs) is a growing priority for performance improvement in clinical care of chronic conditions such as SLE. Measuring…
Abstract Number: 2042 • 2016 ACR/ARHP Annual Meeting
Improving the Overall Pneumococcal Vaccination Rate in Lupus Patients at the Rheumatology Clinic
Shivani Garg¹, Aliza Lipson² and Katina Tsagaris³, ¹Rheumatology, Emory University, Atlanta, GA, ²Rheumatology, EMORY UNIVERSITY, atlanta, GA, ³Rheumatology, EMORY UNIVERSITY, Atlanta, GA
Background/Purpose: The risk of developing invasive pneumococcal pneumonia is 13 times higher in Lupus patients in comparison with general population. CDC anticipates 7.6 Million-Dollar medical…
Abstract Number: 2043 • 2016 ACR/ARHP Annual Meeting
Feasibility and Accuracy of Translating a Patient Safety Quality Measure into an Automated e-Measure
Chris Tonner¹, Gabriela Schmajuk², Laura Trupin³ and Jinoos Yazdany³, ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Physician payments in the U.S. are shifting from fee-for-service to a value-based system, which will require quality measures to be extracted automatically from the…
Abstract Number: 2044 • 2016 ACR/ARHP Annual Meeting
Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus
Amanda M. Eudy^1,2, Anna Maria Siega-Riz², Stephanie Engel², Nora Franceschini², Annie Green Howard³, Megan E. B. Clowse¹ and Michelle Petri⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There are conflicting results about the effect pregnancy has on the health of systemic lupus erythematosus (SLE) women. The objective of the current analysis…
Abstract Number: 2045 • 2016 ACR/ARHP Annual Meeting
Early Preeclampsia Risk in Lupus Pregnancy: A Swedish Population-Based Register Investigation
Julia F Simard^1,2, Elizabeth V. Arkema³, Cathina Nguyen⁴, Elisabet Svenungsson⁵, Anna-Karin Wikstrom^6,7, Kristin Palmsten⁸ and Jane E. Salmon⁹, ¹Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ²Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Health Research & Policy, Stanford School of Medicine, Stanford, CA, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden, ⁷Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁸Department of Pediatrics, University of California, San Diego, La Jolla, CA, ⁹Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Early preeclampsia is a serious pregnancy complication characterized by abnormal placentation and diffuse maternal endothelial cell dysfunction, and requires emergent delivery which may be…
Abstract Number: 2046 • 2016 ACR/ARHP Annual Meeting
The Low-Dose Intravenous Cyclophosphamide Euro-Lupus Regimen Does Not Impact the Ovarian Reserve of Lupus Patients, As Measured By Serum Anti-Mullerian Hormone Levels
Séverine Nieuwland¹, Farah Tamirou¹, Damien Gruson², Frédéric Debiève³, Bernard R. Lauwerys¹ and Frédéric A. Houssiau¹, ¹Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium, ²Clinical Chemistry Department, Cliniques universitaires Saint-Luc, Brussels, Belgium, ³Obstetrics Department, Cliniques universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: The low-dose intravenous (IV) cyclophosphamide (CY) Euro-Lupus (EL) regimen (cumulative dose 3g) has been developped to reduce gonadal toxicity. Although no case of premature menopause…
Abstract Number: 2047 • 2016 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Adey Berhanu³, Cesar Fors-Nieves⁴, Ummara Shah⁵, Patrick Brown⁶, Carl Laskin⁷, Nathalie Morel⁸, Kateri Levesque⁹, Jill P. Buyon¹⁰, Earl Silverman⁶ and Peter M. Izmirly¹¹, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Rheumatology Fellowship Program, NYU Langone Medical Center/NYU School of Medicine, New York, NY, ⁴Division of Rheumatology, NYU School of Medicine, New York, NY, ⁵Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁶University of Toronto, Toronto, ON, Canada, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁹Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ¹⁰Medicine, Tisch Hospital, New York, NY, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Histopathologic studies of cutaneous neonatal lupus erythematosus (cNLE) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in…
Abstract Number: 2048 • 2016 ACR/ARHP Annual Meeting
Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
Megan E. B. Clowse¹, Frauke Förger², Caroline Hwang³, John Thorp⁴, Radboud J. E. M. Dolhain⁵, Astrid van Tubergen⁶, Laura Shaughnessy⁷, Jeff Simpson⁸, Marie Teil⁹, Nathalie Toublanc¹⁰, Maggie Wang⁸ and Thomas W. Hale¹¹, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Keck Hospital of USC, Los Angeles, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Texas Tech University School of Medicine, Amarillo, TX
Background/Purpose: Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding.…
Abstract Number: 2049 • 2016 ACR/ARHP Annual Meeting
Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
Evelyne Vinet¹, Cristiano S. Moura², Jeffrey R. Curtis³, Christian A. Pineau⁴, Michal Abrahamowicz² and Sasha Bernatsky⁵, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, AL, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during RA pregnancy. Most of these are actively transported across the placenta, reaching higher fetal than maternal…
Abstract Number: 2050 • 2016 ACR/ARHP Annual Meeting
Screening for and Management of Comorbidities after a Nurse-Led Program: Results of a 3 Year Longitudinal Study in 776 Established RA Patients
Laure Gossec¹, Martin Soubrier², Frantz Foissac³, Anna Molto⁴, Françoise Fayet⁵, Thomas Bardin⁶, Francis Berenbaum⁷, Alain Cantagrel⁸, Marie Hélène Cerato⁹, Gerard H. Chales¹⁰, Bernard Combe¹¹, Emmanuelle Dernis Labous¹², Isabelle Chary-Valckenaere¹³, Liana Euller-Ziegler¹⁴, Rene-Marc Flipo¹⁵, Philippe Gaudin¹⁶, Melanie Gilson¹⁷, Sandrine Guis¹⁸, Xavier Mariette¹⁹, Gaël Mouterde²⁰, Sophie Pouplin²¹, Pascal Richette²², Alain Saraux²³, Thierry Schaeverbeke²⁴, Jean Sibilia²⁵ and Maxime Dougados²⁶, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³COMEDRA working group, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁶Hôpital Lariboisière, Paris, France, ⁷Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁸Purpan Hospital, Toulouse, France, ⁹University Hospital, Toulouse, France, ¹⁰CHU RENNES, Rennes, France, ¹¹Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹²Le Mans Hospital, Le Mans, France, ¹³University Hospital, Nancy, France, ¹⁴Rheumatology, Nice, France, ¹⁵Rheumatology, University Hospital, Lille, France, ¹⁶Rheumatology, Grenoble University Hospital, France, Grenoble, France, ¹⁷Hopital Sud, Grenoble, France, ¹⁸Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ¹⁹Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ²⁰Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ²¹Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²²Rhumatologie, Hôpital Lariboisière, Paris, France, ²³Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²⁴Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁶Paris Descartes University, Paris, France
Background/Purpose: Patients with RA are either more at risk of, or less well screened for, several comorbidities including cardiovascular (CV) risk, cancer, infections and osteoporosis.[1]…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].